Qing Sang1, Liang Wang1, Qiqige Wuyun2, Xuejing Zheng1, Dezhong Wang3, Nengwei Zhang4, Dexiao Du5. 1. Surgery Centre of Diabetes Mellitus, Peking University Ninth School of Clinical Medicine, Beijing, 100038, China. 2. Surgery Centre of Diabetes Mellitus, Capital Medical University Affiliated Beijing Shijitan Hospital, Beijing, 100038, China. 3. Department of General Surgery, Aerospace Center Hospital, Beijing, 100049, China. 4. Surgery Centre of Diabetes Mellitus, Peking University Ninth School of Clinical Medicine, Beijing, 100038, China. zhangnw1@sohu.com. 5. Surgery Centre of Diabetes Mellitus, Peking University Ninth School of Clinical Medicine, Beijing, 100038, China. dudexiao@sohu.com.
Abstract
BACKGROUND: As a modification of the duodenal switch (DS), single-anastomosis duodenal-ileal bypass with sleeve gastrectomy (SADI-S) has recently become very popular and is successful for weight loss and T2DM remission. However, current studies have been mostly aimed at patients with severe obesity. OBJECTIVES: In this study, we firstly compare primary SADI-S to the Roux-en-Y gastric bypass (RYGB) in Chinese with diabetes and BMI< 35 kg/m2. METHODS: Using a propensity score (PS) matching analysis, we analyzed all patients with diabetes and BMI< 35 kg/m2 who underwent primary SADI-S or RYGB. All surgeries were conducted by a single surgeon at a Chinese center from June 2017 to January 2019. RESULTS: Twenty-six patients who underwent SADI-S and 65 patients who underwent RYGB were included in our analysis. Of these, 26 (100%) of patients in the SADI-S group and 43 (66%) of patients in the RYGB group completed the 24-month follow-up. No severe perioperative complication was observed in either group. There was a statistically higher percentage of total weight loss with SADI-S at the 2-year follow-up when compared to RYGB (p = 0.017 after PS correction). After PS adjustment, 76.5% of patients in the SADI-S group and 82.4% of patients in the RYGB group achieved complete remission of T2DM (p = 1.000). Nutritional outcomes were similar in the two groups. CONCLUSION: In Chinese with diabetes and BMI< 35 kg/m2, with comparable T2DM remission and nutritional outcomes, primary SADI-S allows for better weight loss than RYGB. Compared with RYGB, SADI-S is also a safe, effective, and feasible treatment for these patients.
BACKGROUND: As a modification of the duodenal switch (DS), single-anastomosis duodenal-ileal bypass with sleeve gastrectomy (SADI-S) has recently become very popular and is successful for weight loss and T2DM remission. However, current studies have been mostly aimed at patients with severe obesity. OBJECTIVES: In this study, we firstly compare primary SADI-S to the Roux-en-Y gastric bypass (RYGB) in Chinese with diabetes and BMI< 35 kg/m2. METHODS: Using a propensity score (PS) matching analysis, we analyzed all patients with diabetes and BMI< 35 kg/m2 who underwent primary SADI-S or RYGB. All surgeries were conducted by a single surgeon at a Chinese center from June 2017 to January 2019. RESULTS: Twenty-six patients who underwent SADI-S and 65 patients who underwent RYGB were included in our analysis. Of these, 26 (100%) of patients in the SADI-S group and 43 (66%) of patients in the RYGB group completed the 24-month follow-up. No severe perioperative complication was observed in either group. There was a statistically higher percentage of total weight loss with SADI-S at the 2-year follow-up when compared to RYGB (p = 0.017 after PS correction). After PS adjustment, 76.5% of patients in the SADI-S group and 82.4% of patients in the RYGB group achieved complete remission of T2DM (p = 1.000). Nutritional outcomes were similar in the two groups. CONCLUSION: In Chinese with diabetes and BMI< 35 kg/m2, with comparable T2DM remission and nutritional outcomes, primary SADI-S allows for better weight loss than RYGB. Compared with RYGB, SADI-S is also a safe, effective, and feasible treatment for these patients.
Authors: Andrés Sánchez-Pernaute; Miguel Angel Rubio Herrera; Elia Pérez-Aguirre; Juan Carlos García Pérez; Lucio Cabrerizo; Luis Díez Valladares; Cristina Fernández; Pablo Talavera; Antonio Torres Journal: Obes Surg Date: 2007-11-27 Impact factor: 4.129
Authors: Austin Cottam; Daniel Cottam; Dana Portenier; Hinali Zaveri; Amit Surve; Samuel Cottam; Legrand Belnap; Walter Medlin; Christina Richards Journal: Obes Surg Date: 2017-02 Impact factor: 4.129
Authors: Brian Mitzman; Daniel Cottam; Richie Goriparthi; Samuel Cottam; Hinali Zaveri; Amit Surve; Mitchell S Roslin Journal: Obes Surg Date: 2016-09 Impact factor: 4.129
Authors: Luigi Angrisani; A Santonicola; P Iovino; A Vitiello; K Higa; J Himpens; H Buchwald; N Scopinaro Journal: Obes Surg Date: 2018-12 Impact factor: 4.129
Authors: Phillip J Dijkhorst; Abel B Boerboom; Ignace M C Janssen; Dingeman J Swank; René M J Wiezer; Eric J Hazebroek; Frits J Berends; Edo O Aarts Journal: Obes Surg Date: 2018-12 Impact factor: 4.129